Latest Period
n/a
Security Snapshot
NLS Pharmaceutics Ltd. - Common Share, Par Value CHF 0.03 Per Share (NLSP) Institutional Ownership
CUSIP: H57830103
13F Institutional Holders and Ownership History from Q1 2021 to Q4 2025
Institutions Reporting
Shares (Excl. Options)
Price
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Share, Par Value CHF 0.03 Per Share
- Symbol
- NLSP on Nasdaq
- Shares outstanding
- 4,220,689
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- NLSP - NLS Pharmaceutics Ltd. - Common Share, Par Value CHF 0.03 Per Share is tracked under CUSIP H57830103.
- Latest finished 13F holder period is not available.
- 1 significant owner is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 1 to 0 between Q3 2025 and Q4 2025.
- SEC-reported value moved from $66 to $0.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Schedule 13D/G
Open SEC evidence
Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.
Security key
H57830103
Latest holder period
n/a
13F holders
13D/G owners
1
CIK / CUSIP context first
NLSP full holder history
NewcelX Ltd. SEC filings
NewcelX Ltd. company facts
NewcelX Ltd. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP H57830103:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
1
Security
NLSP
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Hafner Ronald | 13% | 557,131 | Ronald Hafner | 22 May 2025 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
18
Latest
n/a
Rows shown
1-18 of 18
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 0 | $0 | -$66 | 0 | |
| 2025 Q3 | 36 | $66 | $1.83 | 1 | |
| 2025 Q2 | 36 | $104 | +$104 | $2.89 | 1 |
| 2024 Q3 | 0 | $0 | -$1,848,846 | 0 | |
| 2024 Q2 | 8,526,849 | $1,848,846 | +$80,292 | $0.22 | 9 |
| 2024 Q1 | 8,157,932 | $1,478,555 | +$395,483 | $0.18 | 7 |
| 2023 Q4 | 5,830,804 | $3,439,113 | -$323,191 | $0.59 | 5 |
| 2023 Q3 | 6,294,283 | $4,353,798 | -$133,457 | $0.70 | 7 |
| 2023 Q2 | 6,461,209 | $7,107,161 | +$95,119 | $1.10 | 9 |
| 2023 Q1 | 6,365,941 | $9,615,147 | +$871,772 | $1.51 | 7 |
| 2022 Q4 | 5,791,528 | $7,470,487 | +$7,372,279 | $1.29 | 4 |
| 2022 Q3 | 115,273 | $72,000 | -$672,403 | $0.63 | 4 |
| 2022 Q2 | 1,265,273 | $743,000 | +$679,412 | $0.59 | 4 |
| 2022 Q1 | 71,841 | $102,000 | -$54,533 | $1.42 | 5 |
| 2021 Q4 | 131,248 | $145,000 | -$45,414 | $1.11 | 7 |
| 2021 Q3 | 134,723 | $335,000 | +$144,984 | $2.49 | 5 |
| 2021 Q2 | 65,270 | $205,000 | -$78,000 | $3.14 | 4 |
| 2021 Q1 | 70,038 | $283,000 | +$283,000 | $4.03 | 3 |